How tretinoin works: retinoids and skin cell turnover

What retinoids are — and where tretinoin fits

Retinoids are a family of compounds related to vitamin A. The term is an umbrella that covers:

• Naturally occurring forms such as retinol and retinaldehyde
• The acid form known as retinoic acid
• A range of synthetic analogs developed in the laboratory

What ties them together is a shared structural relationship to vitamin A and the ability to interact, directly or after conversion, with the cellular machinery that responds to that vitamin.

Tretinoin is the common name for all-trans retinoic acid, the acid form of vitamin A. This distinction matters mechanistically. Over-the-counter ingredients like retinol and retinaldehyde are precursors: the skin converts them through one or more enzymatic steps into retinoic acid before they can act on the relevant receptors. Tretinoin is already in that receptor-active acid form, so it does not require the same conversion inside the skin.

In the United States, tretinoin is a prescription-only medication. It is studied and used in the context of acne and of photoaging — the skin changes associated with long-term ultraviolet exposure. This article is educational and describes how the molecule is understood to act; it is not medical advice, and a licensed provider evaluates whether any retinoid is appropriate for a given person.

How tretinoin binds retinoic-acid receptors

Tretinoin exerts its activity by binding to a set of proteins called retinoic-acid receptors, or RARs. These are nuclear receptors, meaning they reside inside the cell — near or within the nucleus — rather than sitting on the cell surface. There are several RAR subtypes, commonly labeled alpha, beta, and gamma, and they are found in the cells of the skin along with a related family called retinoid X receptors (RXRs).

When tretinoin binds an RAR, that receptor characteristically pairs with an RXR to form a two-part complex known as a heterodimer. This complex can attach to specific stretches of DNA called retinoic-acid response elements and act as a transcription factor — a molecular switch that turns the reading of particular genes up or down. In other words, tretinoin's mechanism operates at the level of gene expression inside skin cells, not as a coating or a physical exfoliant on the surface.

Because the pathway runs through gene transcription and the protein synthesis that follows, the biological changes it sets in motion unfold over the timescale of ordinary cellular processes rather than instantly. Describing tretinoin as a receptor-binding signaling molecule, rather than a surface treatment, is the most accurate way to frame how it is understood to act.

Skin cell turnover and the keratinocyte cycle

The outer layer of skin, the epidermis, is built largely from cells called keratinocytes. These cells are generated at the base of the epidermis, then gradually migrate upward, changing as they go in a process called differentiation. By the time they reach the surface they have flattened and filled with keratin, and eventually they are shed in a process called desquamation. This continuous cycle of production at the bottom, maturation on the way up, and shedding at the top is what the phrase "skin cell turnover" refers to.

Retinoic-acid signaling is understood to influence the genes that govern how keratinocytes proliferate and differentiate, as well as the proteins that hold neighboring cells together. Through this receptor-driven effect on gene expression, tretinoin is associated with modulating the pace and pattern of the keratinocyte cycle — the rate at which cells are produced, mature, and are shed. This is the epidermal side of its mechanism.

Framing it this way keeps the focus on biology rather than on any promised outcome. Tretinoin is discussed in relation to skin surface renewal because of how it is understood to act on the turnover cycle at the level of gene signaling, and how that mechanism plays out for any individual is something a clinician assesses in context.

Collagen and the dermal matrix

Beneath the epidermis lies the dermis, a deeper layer that gives skin much of its structure. The dermis contains cells called fibroblasts, which produce collagen and the surrounding network of proteins known as the extracellular matrix. Retinoic-acid receptors are present in these deeper cells too, so the same receptor pathway that operates in the epidermis extends into the dermis.

In the dermis, retinoic-acid signaling is understood to influence the expression of genes involved in collagen production, as well as genes for a group of enzymes called matrix metalloproteinases (MMPs) that break collagen down. The interplay between collagen being made and collagen being degraded is part of how the dermal matrix is continuously maintained, and this signaling is where tretinoin is understood to act within that layer.

The dermal collagen-signaling mechanism is distinct from the epidermal turnover mechanism, even though both trace back to the same retinoic-acid receptors. Describing tretinoin therefore means describing two connected layers of activity — one shaping how surface cells cycle, the other shaping gene signaling around collagen in the tissue below.

Forms, formulation, and why it is prescription-only

Tretinoin is most commonly prepared for topical use and applied to the skin. It is formulated in vehicles such as creams and gels and is made in a range of strengths. The base or vehicle a formulation uses affects how the ingredient is absorbed and how much reaches the different layers of skin, which is one reason formulation is a considered choice rather than an afterthought. Compounding pharmacies may also prepare tretinoin in a particular strength or base, or combined with other ingredients, in response to a specific prescription; a compounded preparation is not itself FDA-approved, though the pharmacy that prepares it is a licensed, regulated facility.

Tretinoin also carries known characteristics that shape how it is handled clinically. It is associated with increased skin sensitivity to sunlight and ultraviolet light, and retinoids as a class involve considerations related to pregnancy and to certain skin conditions and other medications. These are among the factors a reviewing provider weighs — not usage instructions to follow from an article — which is precisely why tretinoin is prescription-only in the United States and why an evaluation by a licensed provider sits at the center of the process. Nothing here is a substitute for that clinical judgment.

How prescription review works on OpenDoseRx

On OpenDoseRx, the process is designed so that a clinician — not the shopper — makes the medical decision. You begin by choosing a product and the strength or formulation you are interested in, so the exact preparation and its price are clear up front. You then complete a medical intake that collects your health history, current medications, and other relevant information.

That intake is routed to an independent, licensed U.S. provider who reviews it and decides whether a prescription is appropriate for you. If the provider determines it is, the prescription is sent to a licensed U.S. pharmacy to be filled and shipped to you. If the request is declined, you are not charged for the medication and receive a full refund. Every product is prescription-only, and nothing here replaces a conversation with your own healthcare provider — the reviewing clinician and dispensing pharmacy carry the clinical and professional responsibility.